Welcome to our dedicated page for Contineum Therapeutics SEC filings (Ticker: CTNM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Contineum Therapeutics, Inc. (CTNM) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as a Nasdaq-listed clinical-stage biopharmaceutical issuer. Contineum files current reports on Form 8-K to describe material events such as clinical data readouts, financing transactions, shareholder votes and trial design updates, alongside its other periodic SEC reports.
For CTNM, clinical development milestones are a recurring theme in its filings. Form 8-K reports have summarized topline data from the PIPE-307 Phase 2 VISTA trial in relapsing-remitting multiple sclerosis and positive topline data from the PIPE-791 Phase 1b PET trial assessing LPA1 receptor occupancy in healthy volunteers and progressive multiple sclerosis patients. Another 8-K details the design of a 26-week, international, randomized, double-blind, placebo-controlled Phase 2 trial of PIPE-791 in idiopathic pulmonary fibrosis, including its primary efficacy measure based on change in forced vital capacity.
Filings also document capital markets activity. Contineum has reported entering into an underwriting agreement for an upsized public offering of its Class A common stock under a shelf registration statement on Form S-3, as well as prior at-the-market offerings. These disclosures outline the terms of offerings, estimated net proceeds and related exhibits such as underwriting agreements and legal opinions.
Investors can use this page to review CTNM’s governance and shareholder matters, including results of its annual meeting of stockholders reported on Form 8-K, where director elections and auditor ratification votes are recorded. With real-time updates from EDGAR and AI-powered summaries, this filings page helps readers quickly understand the key points in Contineum’s 8-Ks and related exhibits, while still allowing full-text access to the underlying SEC documents for deeper analysis.
Contineum Therapeutics (CTNM) – Form 4 Insider Filing
On 06/26/2025, non-employee director Lori Lyons-Williams reported the grant of a stock option covering 14,750 shares of Class A common stock. The option, issued under the company’s 2024 Equity Incentive Plan and the Non-Employee Director Compensation Program, carries an exercise price of $4.01 and expires on 06/25/2035. Vesting occurs in full on the earlier of (i) 06/26/2026 (one-year anniversary of grant) or (ii) the next annual meeting of shareholders, contingent on continued board service. Following the grant, the reporting person beneficially owns 14,750 derivative securities; no common shares were purchased or sold. This represents a routine compensation award and does not alter the company’s share count in the near term.
Contineum Therapeutics, Inc. (CTNM) – Form 4 filing dated June 26, 2025
Non-employee director Olivia C. Ware received an automatic annual stock-option award under the company’s 2024 Equity Incentive Plan. The grant covers 14,750 options to purchase Class A common shares at an exercise price of $4.01 per share. The options vest in full on the earlier of (i) June 26, 2026 (one-year anniversary) or (ii) the next regular annual meeting of stockholders, contingent on continued board service, and expire on June 25, 2035. Following the grant, Ware beneficially owns 14,750 derivative securities, reported as direct ownership. No common shares were bought or sold, and no cash changed hands; the transaction is a routine component of the board’s compensation program and results in only de-minimis dilution to existing shareholders.
Form 4 Overview – Contineum Therapeutics, Inc. (CTNM)
Director Diego G. Miralles reported a routine equity award on 26 June 2025. Under the company’s 2024 Equity Incentive Plan and the Non-Employee Director Compensation Program, he received a stock option for 14,750 Class A shares at an exercise price of $4.01 per share. The option vests in full on the earlier of 26 June 2026 or the next annual shareholder meeting and expires on 25 June 2035. Following the grant, Miralles beneficially owns 14,750 derivative securities, all held directly.
No common shares were bought or sold, and no cash changed hands at the time of grant; the filing merely reflects an incentive-alignment award typical for non-employee directors.
Contineum Therapeutics (Nasdaq: CTNM) filed a routine Form 8-K reporting the voting outcomes of its 2025 virtual Annual Meeting held on June 26, 2025.
Shareholders re-elected Class I directors Sarah Boyce, Troy Ignelzi and Olivia Ware, and ratified Ernst & Young LLP as independent auditor for fiscal 2025. No additional proposals or material events were disclosed.